In this podcast, we are joined by Dr. Andrew Steele, nephrologist at Lakeridge Health. He discusses the efficacy and safety considerations in patients with atrial fibrillation and chronic kidney disease, Canadian recommendations for appropriate dosing of NOACs and how clinicians can limit the progression of renal impairment in their patients.

This program was made available through funding from Bayer.